SLC35E1

Solute carrier family 35 member E1 · Q96K37 · SLC35E1 on Sugi Atlas →

0 patent compounds predicted against SLC35E1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SLC35E1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Age on the Renal Clearance of Adefovir PHASE4WITHDRAWN
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1 PHASE1COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC PHASE1COMPLETED
Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers PHASE1COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study nanCOMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Role of the ATP7A Transporter in Ovarian Cancer nanCOMPLETED
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Genetically Guided Statin Therapy nanCOMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response nanCOMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient nanUNKNOWN
Gyrate Atrophy Ocular and Systemic Study nanACTIVE_NOT_RECRUITING
ADPKD Alterations in Hepatic Transporter Function nanCOMPLETED
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease nanNOT_YET_RECRUITING
Individualized Antiretroviral Therapy nanCOMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features nanUNKNOWN
Genetic Variants and Iron Absorption nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC35E1 binder may also engage these)

ProteinNameSimilarity
P0C6B1 1.000 P0C6B1 →
Q8CD26 0.996 Q8CD26 →
SLC35B2 Adenosine 3'-phospho 5'-phosphosulfate transporter 1 0.954 landscape →
Q91ZN5 0.950 Q91ZN5 →
Q5R9A1 0.947 Q5R9A1 →
Q9SS40 0.938 Q9SS40 →
Q91WC7 0.936 Q91WC7 →
Q8H184 0.934 Q8H184 →
Q9VR50 0.934 Q9VR50 →
Q8R314 0.934 Q8R314 →
A8MRY9 0.934 A8MRY9 →
Q84L09 0.934 Q84L09 →
Q8WV83 0.933 Q8WV83 →
Q9SFE9 0.933 Q9SFE9 →
Q8IY50 0.930 Q8IY50 →
Q5R6J3 0.930 Q5R6J3 →
Q8R070 0.930 Q8R070 →
Q96HV5 0.930 Q96HV5 →
A6QL92 0.930 A6QL92 →
Q1LZI2 0.930 Q1LZI2 →
Q9H841 0.928 Q9H841 →
Q9D8U2 0.927 Q9D8U2 →
Q4R794 0.926 Q4R794 →
Q08D99 0.925 Q08D99 →
Q7RTT9 0.925 Q7RTT9 →
Q6NM25 0.924 Q6NM25 →
Q12887 0.924 Q12887 →
Q9FDZ5 0.924 Q9FDZ5 →
Q8CFY5 0.923 Q8CFY5 →
Q9LNK7 0.923 Q9LNK7 →